Immunochemotherapy prevents human colon cancer metastasis after orthotopic onplantation of histologically-intact tumor tissue in nude mice. 1993

T Furukawa, and T Kubota, and M Watanabe, and T H Kuo, and S Kase, and Y Saikawa, and H Tanino, and T Teramoto, and K Ishibiki, and M Kitajima
Department of Surgery, School of Medicine, Keio University, Tokyo, Japan.

A metastatic model of human colon cancer has been previously established using orthotopic onplantation of histologically intact in tissue nude mice. In this study, effects of immunochemotherapy using OK-432, 5-fluorouracil (5-FU) and mitomycin C (MMC) on Col-2-JCK, a human colon cancer xenograft, were evaluated using this model. When 5-FU and MMC were administered without OK-432, liver metastases were not reduced even at maximum tolerated doses of both drugs, although cecal tumor growth was significantly reduced. On the other hand, when combined with OK-432, both 5-FU and MMC reduced liver metastases with synergistic reduction of cecal tumor growth, demonstrating the potential of combining immunotherapy with chemotherapy against metastases.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D008114 Liver Neoplasms, Experimental Experimentally induced tumors of the LIVER. Hepatoma, Experimental,Hepatoma, Morris,Hepatoma, Novikoff,Experimental Hepatoma,Experimental Hepatomas,Experimental Liver Neoplasms,Hepatomas, Experimental,Neoplasms, Experimental Liver,Experimental Liver Neoplasm,Liver Neoplasm, Experimental,Morris Hepatoma,Novikoff Hepatoma
D008297 Male Males
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D009368 Neoplasm Transplantation Experimental transplantation of neoplasms in laboratory animals for research purposes. Transplantation, Neoplasm,Neoplasm Transplantations,Transplantations, Neoplasm
D010844 Picibanil A lyophilized preparation of a low-virulence strain (SU) of Streptococcus pyogenes (S. hemolyticus), inactivated by heating with penicillin G. It has been proposed as a noncytotoxic antineoplastic agent because of its immune system-stimulating activity. NSC-B116209,OK-432,Picibanyl,Streptococcal OK-432,Streptococcal Preparation OK-432,NSC B116209,NSCB116209,OK 432,OK432,Streptococcal OK 432,Streptococcal OK432,Streptococcal Preparation OK 432,Streptococcal Preparation OK432
D002430 Cecal Neoplasms Tumors or cancer of the CECUM. Cancer of Cecum,Cecal Cancer,Cancer of the Cecum,Cancer, Cecal,Neoplasms, Cecal,Cecal Neoplasm,Neoplasm, Cecal
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal

Related Publications

T Furukawa, and T Kubota, and M Watanabe, and T H Kuo, and S Kase, and Y Saikawa, and H Tanino, and T Teramoto, and K Ishibiki, and M Kitajima
January 1992, Anticancer research,
T Furukawa, and T Kubota, and M Watanabe, and T H Kuo, and S Kase, and Y Saikawa, and H Tanino, and T Teramoto, and K Ishibiki, and M Kitajima
December 1992, International journal of cancer,
T Furukawa, and T Kubota, and M Watanabe, and T H Kuo, and S Kase, and Y Saikawa, and H Tanino, and T Teramoto, and K Ishibiki, and M Kitajima
December 1991, International journal of cancer,
T Furukawa, and T Kubota, and M Watanabe, and T H Kuo, and S Kase, and Y Saikawa, and H Tanino, and T Teramoto, and K Ishibiki, and M Kitajima
November 2004, World journal of gastroenterology,
T Furukawa, and T Kubota, and M Watanabe, and T H Kuo, and S Kase, and Y Saikawa, and H Tanino, and T Teramoto, and K Ishibiki, and M Kitajima
October 1991, Proceedings of the National Academy of Sciences of the United States of America,
T Furukawa, and T Kubota, and M Watanabe, and T H Kuo, and S Kase, and Y Saikawa, and H Tanino, and T Teramoto, and K Ishibiki, and M Kitajima
January 1993, Anticancer research,
T Furukawa, and T Kubota, and M Watanabe, and T H Kuo, and S Kase, and Y Saikawa, and H Tanino, and T Teramoto, and K Ishibiki, and M Kitajima
March 1997, Clinical & experimental metastasis,
T Furukawa, and T Kubota, and M Watanabe, and T H Kuo, and S Kase, and Y Saikawa, and H Tanino, and T Teramoto, and K Ishibiki, and M Kitajima
January 1993, Anticancer research,
T Furukawa, and T Kubota, and M Watanabe, and T H Kuo, and S Kase, and Y Saikawa, and H Tanino, and T Teramoto, and K Ishibiki, and M Kitajima
May 2016, Anticancer research,
T Furukawa, and T Kubota, and M Watanabe, and T H Kuo, and S Kase, and Y Saikawa, and H Tanino, and T Teramoto, and K Ishibiki, and M Kitajima
April 1996, International journal of cancer,
Copied contents to your clipboard!